RAPID relative to TAP, MCIT, and TCET
A few years ago, there was a moment—brief, but telling—when it looked like Medicare might finally collapse the gap between FDA approval and coverage.
That moment was Medicare Coverage of Innovative Technologies, or MCIT. The idea was almost simple: if the FDA designates a device as “breakthrough,” Medicare would cover it automatically for four years. No prolonged national coverage determinations. No drawn-out evidence debates. Just… access. For a field that has lived with multi-year delays between approval and reimbursement, it felt like a release valve.
CMS pulled it back before it ever truly launched. Not because the goal was wrong, but because the premise was incomplete. FDA approval answers one question—does the technology work? Medicare has to answer a different one—does it work well enough, in an older and more medically complex population, to justify broad coverage?
That tension didn’t go away. It just got reframed. What followed (TCET, TAP, and now emerging concepts like RAPID) is not a continuation of MCIT. It’s a correction.
TCET, in particular, tells you exactly where CMS landed philosophically. Instead of automatic coverage, TCET creates a structured, negotiated pathway. Manufacturers engage earlier. Evidence expectations are clarified before FDA approval. Coverage can begin sooner—but only if it is tied to a plan for continued evidence generation.
It sounds like progress, and in many ways it is. The process is more predictable. The rules are clearer. The surprises are fewer. But there’s a detail that tends to get glossed over: TCET is intentionally narrow. CMS has signaled that only a handful of technologies will move through this pathway each year. That’s not a broad solution. It’s a controlled experiment.
And that matters, because it changes how you should interpret its success. If TCET works well, it won’t be because it accelerated access across the market. It will be because it created a high-confidence lane for a small number of well-prepared technologies.
At the same time, FDA introduced TAP—the Total Product Lifecycle Advisory Program.
TAP doesn’t grant coverage. It doesn’t make reimbursement decisions. What it does is quieter, but arguably just as important: it brings FDA, CMS, and other stakeholders into the same conversation earlier in the process.
For years, companies have optimized clinical evidence for regulatory approval, only to discover (too late) that payers were asking a different set of questions. TAP is an attempt to eliminate that disconnect before it becomes expensive.
But it’s worth being precise about its impact. Alignment is not acceleration. You can be perfectly aligned and still not have coverage. TAP reduces the risk of missteps; it does not remove the burden of proof.
Now there’s increasing discussion around what comes next, the recently announced RAPID program. Whether or not that exact framework takes hold, the direction is clear. There is pressure to move faster, to rely more on real-world evidence, and to create mechanisms that allow earlier access while data is still maturing.
In other words, the system is still searching for the balance MCIT tried to strike in one step.
So where does that leave us? If you step back, these programs aren’t contradictory. They’re iterative.
MCIT prioritized speed and lost payer confidence.
TCET prioritizes evidence and limits scale.
TAP prioritizes alignment but doesn’t control outcomes.
RAPID is trying—again—to push the system toward faster decisions without losing rigor.
None of them, on their own, solve the problem. But together, they signal something more important: Medicare is not moving toward automatic coverage. It is moving toward earlier scrutiny.
That shift has practical consequences. The old sequencing (regulatory first, reimbursement later) is breaking down. Not because CMS has formally changed the rules, but because the pathways now reward companies that behave as if reimbursement starts on Day One.
The technologies that will move fastest are not necessarily the most novel. They’re the ones that anticipate Medicare’s questions early, design evidence accordingly, and engage before decisions are locked in.
There’s a tendency to look at these programs and ask whether they are “working.”
A better question is: what behavior are these programs rewarding?
Medicare is not moving toward automatic coverage for FDA-authorized technologies. It is moving toward earlier, more structured evaluation of whether the evidence is sufficient for the Medicare population, whether remaining uncertainty can be addressed through post-market data collection, and whether coverage can be limited while that evidence matures.
For MedTech companies, the implication is significant. FDA strategy and reimbursement strategy can no longer run on separate tracks. A pivotal study designed only for regulatory clearance may leave major coverage questions unanswered. That can delay adoption, weaken investor confidence, and force companies into expensive evidence-generation work after commercialization should already be underway.
The companies most likely to benefit from TCET, TAP, RAPID-style models, or future versions of these programs will be the ones that can show CMS:
the technology addresses a meaningful unmet need for Medicare beneficiaries;
the clinical evidence includes or reasonably applies to the Medicare population;
the outcomes measured are meaningful to patients, clinicians, and payers;
the post-market evidence plan is credible, operationally feasible, and not merely aspirational; and
the company understands how coverage, coding, and payment will work in real clinical settings.
The broader trend is not “faster Medicare coverage.” It is conditional acceleration for technologies with stronger evidence planning.
That distinction matters. For MedTech companies, these programs should not be treated as shortcuts around reimbursement strategy. They should be treated as signals of how CMS expects innovators to behave: engage earlier, define the evidence gap sooner, build payer-relevant endpoints into the development plan, and avoid assuming that FDA authorization will carry the product across the access finish line.
Do you have U.S. commercialization questions?
Whether it's how the multiple payer landscape works in the U.S., how to validate device or procedure coding, timelines associate with product uptake - we're happy to answer them.
🔗Schedule an introductory call: https://calendly.com/nicolecoustier/introductions
